報價延遲最少15分鐘:2025/05/13 17:34 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.09/-4.23
|
|
企業價值
44.80M
|
| 資產負債 |
|
每股賬面淨值
0.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.34M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 17:34 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). |